SCHEMBL3373664

SCHEMBL3373664

O=C(CCCC1=COC=C(C2=CC=CCC2)O1)N1CCN(CCOc2ccc(F)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
KCNA5 P22460 1/20 0.40
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
DRD3 P35462 5/20 0.38
HRH2 P25021 5/20 0.37
HRH1 P35367 5/20 0.37
DRD2 P14416 1/20 0.37
CACNA1F O60840 2/20 0.37
DRD4 P21917 2/20 0.37
DRD5 P21918 2/20 0.37
ADRA1D P25100 2/20 0.37
HTR2A P28223 2/20 0.37
HTR7 P34969 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37
OPRM1 P35372 2/20 0.37
OPRD1 P41143 2/20 0.37
OPRK1 P41145 2/20 0.37
HTR6 P50406 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2157388 0.86 KCNA5 (0.42) KCNA5MAPTDRD3DRD2ALDH1A1
SCHEMBL2158175 0.73 LTA4H (0.35) LMNAKCNA5DRD3HRH1DRD2
SCHEMBL3775162 0.70 MEN1 (0.41) HRH2HRH1DRD4ADRA1DHTR2A
SCHEMBL7030072 0.70 DRD3 (0.63) KCNA5POLBDRD3HRH2HRH1
Hydrochloric Acid SCHEMBL2157444 0.69 DRD3 (0.61) KCNA5POLBDRD3HRH2HRH1
SCHEMBL2157412 0.68 DRD3 (0.54) LMNAKCNA5POLBMAPTDRD3
SCHEMBL2158174 0.68 TRPV1 (0.48) LMNAKCNA5POLBMAPTDRD3
SCHEMBL2158003 0.67 GFER (0.61) LMNAKCNA5POLBMAPTDRD3
SCHEMBL5024700 0.67 DRD3 (0.63) KCNA5POLBMAPTDRD3HRH2
SCHEMBL2158309 0.67 ME2 (0.60) LMNAKCNA5DRD3HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183374-B2 Piperidine and piperazine derivatives M'S SCIENCE CORPORATION (JP) 2012-05-22 US disclosed
EP-1976525-B1 PIPERIDINE AND PIPERAZINE DERIVATIVES MS SCIENCE CORP (JP) 2010-11-03 EP disclosed
US-20100137334-A1 Piperidine and Piperazine Derivatives SUN CONNIE L 2010-06-03 US disclosed
EP-1976525-A4 PIPERIDINE AND PIPERAZINE DERIVATIVES MS SCIENCE CORP (JP) 2009-07-15 EP disclosed
EP-1976525-A2 PIPERIDINE AND PIPERAZINE DERIVATIVES M's Science Corporation (JP) 2008-10-08 EP disclosed
WO-2007089462-A2 PIPERIDINE AND PIPERAZINE DERIVATIVES M'S SCIENCE CORPORATION (JP) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137334-A1 Piperidine and Piperazine Derivatives SIGMAR1, OPRM1, OPRD1 LMNA 1662/4885KCNA5 273/4885POLB 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.